Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs

Table of Contents

1. Introduction: Multiple Sclerosis

• 1.1 Relapsing-remitting MS
• 1.2 Secondary Progressive MS
• 1.3 Primary Progressive MS
• 1.4 Progressive-relapsing MS
• 1.5 FDA-Approved Drugs for the Treatment of Multiple Sclerosis

2. Global Multiple Sclerosis Market

• 2.1 Market Size
  • 2.1.1 Market Value
  • 2.1.2 Prevalence Rate
  • 2.1.3 Mortality Statistics
• 2.2 Multiple Sclerosis Injectable: Market Share
  • 2.2.1 Injectables Market Value
  • 2.2.2 Market Share

3. US Multiple Sclerosis Market

• 3.1 Market Overview
• 3.2 Prevalence Rate
• 3.3 U.S. Injectables Market
  • 3.3.1 MS Injectables Market

4. Industry Trends

• 4.1 Prevalence of CRPS in Multiple Sclerosis Patients
• 4.2 Environment Causes Increase in Multiple Sclerosis Cases
• 4.3 Increasing Female to Male ratio for Multiple Sclerosis
• 4.4 Demand of MS Diagnosis

5. Opportunities

• 5.1 Oral MS Drugs to Replace Injectables
• 5.2 Opportunities in Asian Region

6. Competitive Landscape

• 6.1 Market Share

7. Company Profiles

• 7.1 Teva Pharmaceutical Industries
  • 7.1.1 Overview
  • 7.1.2 Business Strategies
  • 7.1.3 Expanding its Reach
  • 7.1.4 Broad Product Portfolio
  • 7.1.5 Operating Leverage
• 7.2 Biogen
  • 7.2.1 Overview
  • 7.2.2 Business Strategies
  • 7.2.3 Strategic Agreements
  • 7.2.4 Vast Geographical Presence
• 7.3 Elan Corporation
  • 7.3.1 Overview
  • 7.3.2 Business Strategies
  • 7.3.3 Collaborations and Agreements
• 7.4 Merck Serono S.A.
  • 7.4.1 Overview
  • 7.4.2 Business Strategies
  • 7.4.3 Expansion Project for Erbitux
  • 7.4.4 Diversified Geographic Presence
  • 7.4.5 Broad Product portfolio

8. Market Outlook

List of Tables

• FDA-Approved Drugs for the Treatment of Multiple Sclerosis
• Population Suffering from MS and Prevalence Rate by Region
• US Multiple Sclerosis Injectables Market by Penetration Rate (2005-10E)
• US Multiple Sclerosis Injectables Market Value by Drugs (2005-08E)
• Expected Prevalence of CRPS in MS Patients by Age Group (2007)
• Oral Drugs in Late-stage Development for MS
• Competing Drugs in Development for MS

List of Charts

• Mortality Statistics by Multiple sclerosis by Region (2007)
• Market Value of Multiple Sclerosis Treatment (2001-08)
• Multiple Sclerosis Injectable Market Share (2007)
• MS Injectables Market Value by Drugs (2007)
• Tysabri MS Market Value & Projection (2007-09E)
• Avonex Market Value & Projection (2005-12E)
• Multiple Sclerosis Prevalence in United States (2005-14E)
• US MS Affected Population by Categories (2006)
• Tysabri Market in United States (2006-08)
• Avonex Market Value & Projection for US (2005-12E)
• Smoking Among High School Students vs. Men (2001-05)
• Number of Deaths Attributable to Smoking in China (2005)
• Male/female Ratio of MS in WHO Regions and World (2007)
• Commonest MS Diagnostic Criteria Used (2007)
• Commonest MS diagnostic Criteria Used in WHO Regions (2007)
• US MS Therapies Prescription Trends (2006-07)
• US Market for MS Treatment (2009-12E)
• United States MS Drugs Revenue by Class (2009-12E)
• Teva Pharmaceutical Revenue by Business Segments (2007-08)
• Biogen Revenue by Geography (2006-08)
• Elan Corporation Revenue by Business Segments (2006-08)